Senhwa Advances CX-5461 in Photoimmunotherapy Research
TAIWAN, August 12, 2026 Senhwa Biosciences, Inc. has announced new research findings involving its investigational cancer drug Pidnarulex (CX-5461),...
Stargardt disease
Advertisement
Belite Bio Wins FDA Priority Review for Tinlarebant NDA
SAN DIEGO, California, August 11, 2026 Belite Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026
SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...
Atsena Selects ATSN-401 for Stargardt Disease
DURHAM, N.C., July 9, 2026 Atsena Therapeutics announced the selection of ATSN-401 as its lead clinical candidate for the...
Belite Bio Highlights DRAGON Trial at ISCEV and ASRS
SAN DIEGO, July 6, 2026 Belite Bio announced that new clinical data from its Phase 3 DRAGON trial evaluating...
Advertisements
Nanoscope Therapeutics Highlights MCO-010 Vision Data at ASGCT 2026
DALLAS, May 11, 2026 Nanoscope Therapeutics announced multiple scientific presentations at the American Society of Gene and Cell Therapy...
Ascidian Therapeutics Advances ACDN-01 in Stargardt Trial
BOSTON, MASSACHUSETTS, May 04, 2026 Ascidian Therapeutics has announced the completion of the adult dose escalation phase in its...
Ocugen Completes Dosing in Phase 2/3 Stargardt Trial
MALVERN, Pa., USA — April 1, 2026 Ocugen, Inc. has announced the early completion of dosing in its Phase...
Phase 1 Gene Therapy Data Shows Promise in Stargardt Disease
MALVERN, Pa., January 12, 2026 — Ocugen, Inc. announced the peer-reviewed publication of positive Phase 1 GARDian1 clinical trial...
Tinlarebant Phase 3 Trial Marks Major Breakthrough for STGD1
San Diego, December 1, 2025 — Belite Bio has announced positive topline results from the pivotal global Phase 3...
Advertisement
